Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
Rib-X raises $18.7M for trial of skin infection drug
Rib-X Pharmaceuticals, which specializes in infectious disease drugs, secured $18.7 million in the first tranche of a stock financing round targeted at $67.5 million. The firm will use the proceeds to fund a late-stage trial of delafloxacin, an advanced antibiotic designed to treat acute bacterial skin and skin structure infections such as methicillin-resistant Staphylococcus aureus.
The Hartford Courant (Conn.) (11/29), Mass High Tech (Boston) (11/29)
Or we can send an email on your behalf